Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
NextCure, Inc. (NXTC)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/03/2023 |
8-K
| Quarterly results |
| 03/02/2023 |
8-K
| Quarterly results |
| 08/04/2022 |
8-K
| Quarterly results |
| 05/05/2022 |
8-K
| Quarterly results |
| 03/03/2022 |
8-K
| Quarterly results |
| 11/04/2021 |
8-K
| Quarterly results|
Docs:
|
"NEXTCURE, INC. CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 Revenue: Revenue from former research and development arrangement $ — $ — $ — $ 22,378 Operating expenses: Research and development 13,597 12,740 37,928 34,448 General and administrative 4,911 4,659 15,766 12,918 Total operating expenses 18,508 17,399 53,694 47,366 Loss from operations Other income, net 578 1,032 1,244 3,846 Net loss $ $ $ $ Loss per share - basic and diluted $ $ $ $ Weighted-average shares outstanding - basic and diluted 27,615,038 27,547,737 27,607,685 27,524,350 Comprehensive loss: Net loss $ $ $ $ Unrealized gain on marketable securities 66 1,298 Total comprehensive loss $ $ $ $ NEXTCURE, INC. CONDENSED BALANCE..." |
|
| 08/05/2021 |
8-K
| Quarterly results |
|
|